Article
Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis.
Liver international : official journal of the International Association for the Study of the Liver - 1 Sept 2018
Asselah Tarik, Reesink Hendrik, Gerstoft Jan, de Ledinghen Victor, Pockros Paul J, Robertson Michael, Hwang Peggy, Asante-Appiah Ernest, Wahl Janice, Nguyen Bach-Yen, Barr Eliav, Talwani Rohit, Serfaty Lawrence
Abstract excerpt
BACKGROUND & AIMS: The aim of this integrated analysis was to assess the efficacy of the once-daily combination of elbasvir 50 mg and grazoprevir 100 mg, with and without ribavirin in HCV genotype 4 (GT4)-infected participants enrolled in the Phase 2/3 clinical programme with elbasvir/grazoprevir. METHODS: Treatment-naïve and treatment-experienced participants 18 years of age or older with chronic HCV GT4...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.